VX-745 p38 MAPK Inhibition for Episodic Memory Improvement

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for dementia, particularly Alzheimer's disease, fail to slow or reverse the progression of cognitive decline, and there is a need for therapies that can improve mental function and episodic memory in individuals with or at risk of developing dementia.

Innovation Solution

Administration of VX-745, a p38 MAPK inhibitor, has been shown to improve episodic memory and stabilize or enhance mental functions such as memory, communication, attention, reasoning, and visual perception in individuals with or at risk of dementia, as demonstrated by improvements in MMSE, WMS, and HVLT-R scores.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If current treatments for dementia are administered, then the disease progression is managed, but cognitive decline is not slowed or reversed

Engineering Contradiction:

Improveeffectiveness of dementia treatmentVSAvoidcognitive function maintenance

Core Design Contradiction:

ReliabilityVSProductivity

Solution Approach 1:

The patent applies parameter changes by modifying the biochemical environment in the brain through p38 MAPK inhibition. VX-745 changes the phosphorylation state of target proteins, altering signaling pathways that regulate synaptic plasticity and memory formation. This biochemical parameter change enables improvement of episodic memory and cognitive function in dementia patients, moving beyond mere disease management to actual functional improvement.

Inventive Principle:

Principle #35Parameter changes

2Productivity

If VX-745 is administered, then episodic memory and mental function are improved, but potential side effects and treatment complexity arise

Engineering Contradiction:

Improveepisodic memory functionVSAvoidtreatment regimen complexity

Core Design Contradiction:

ProductivityVSDevice complexity

Solution Approach 1:

VX-745 acts as an intermediary molecule that selectively inhibits p38 MAPK, a specific kinase in the signaling pathway. This intermediary approach allows targeted modulation of the disease process without requiring complex combination therapies. The drug mediates its effect by binding to the ATP-binding site of p38 MAPK, preventing phosphorylation of downstream targets and thereby improving cognitive function through a single, well-defined mechanism.

Inventive Principle:

Principle #24Intermediary (Mediator)

Data Source

PatentEP3445369B1VX-745 for use in the treatment of dementia

Publication Date: 2026.03.25 EIP PHARMA LLC

Figure 1
Figure 2
Figure 3

AI summary

The present invention provides methods and compositions for improving episodic memory and treating dementia.